drugset
drugset / Trial / NCT06509009

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT06509009 ↗

Phase 2 Recruiting 30 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to learn the efficacy and safety of nimotuzumab combined with toripalimab and gemcitabine/cisplatin regimen treatment recurrent/distant-metastasis nasopharyngeal carcinoma.

Timeline

Start
2024-08-30
Primary completion
2026-05-30
Completion
2027-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Nimotuzumab Monoclonal antibody — —
Background Cisplatin Other / unclassified — —
Background Gemcitabine Small molecule — —
Background Toripalimab Monoclonal antibody — —

Indications

nasopharyngeal carcinoma